Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-PSMA CAR-NK in mCRPC
NCT07298239Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Primary completion
- Apr 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-PSMA CAR-NK cells (CIH-CAMS) in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Occurrence of treatment related adverse events as assessed by CTCAE v5.0 at 1 year. Started Dec 2025; status: recruiting.
02
Drugs
anti-PSMA CAR-NK cells (CIH-CAMS)
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07298239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07298239.